Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
The study “Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A,” presents results from a single-arm, phase II trial in advanced sarcomas other than WD/DD-LPS and indicates that Palbociclib, a drug that specifically inhibits proteins called cyclin-dependent kinases 4 and 6 (CDK4/CDK6), has activity in tumors demonstrated to express CDK4 and another protein called CDKN2A. The study demonstrates a promising median progression free survival and overall survival in heavily pretreated patients. These results indicate that CDK4/6 inhibitors may have a role in the treatment of advanced sarcoma patients whose tumors overexpress CDK4.